Led By a World Class Executive Team

Our team is dedicated to building a leading non-opioid analgesic and neurology specialty pharmaceutical company.

R. Scott Shively R. Scott Shively
Chief Executive Officer

Scott Shively is an experienced senior leader in the U.S. and international pharmaceutical markets with extensive COO and CCO experience. He has deep expertise in marketing, sales, managed markets and business development/M&As, with demonstrated ability to lead, rapidly create and grow organizations, develop strategy and execute to deliver results and drive rapid growth in sales and value for shareholders.

Scott has most recently served as chief commercial officer and senior vice president for Depomed, where he led the 400-person, six-brand commercial business for the dynamically growing Pain & CNS Specialty Pharmaceutical company. During his time at Depomed, the company’s net sales increased by 199 percent annually, and he led commercial and all functional efforts in a $1.05 billion acquisition and re-launch of the Nucynta products from Johnson & Johnson. Prior to Depomed, Scott served as executive vice president and chief commercial officer of Zogenix, where he directed all commercial efforts of the company, built the commercial organization and launched a new pain product in record time. From 2009 to 2012, he was vice president and global commercial disease area lead for pain for Pfizer, Inc., where he had global commercial leadership responsibility for all of Pfizer’s marketed and development stage pain products, including Lyrica and Celebrex, with accountability for over $6.5 billion in revenues.


Ilona Steigerwald, MDIlona Steigerwald, MD
Chief Medical Officer

Dr. Ilona Steigerwald brings to Neumentum 20 years of international and cross-cultural pharmaceutical experience, with a focus on innovative treatments for acute and chronic pain. Most recently, she was Business Lead of late research and development at Grünenthal GmbH. There, she led research and development strategies for a late-stage portfolio focused in analgesia, central nervous system and orphan drugs. She has worked on a variety of opioid and non-opioid pain products and product candidates including tramadol, tramadol-acetaminophen, transdermal buprenorphine, topical lidocaine patch, tapentadol for acute and chronic pain, a sufentanil-related device for acute postoperative pain and various licensing opportunities in the field. Dr. Steigerwald has written over 30 full-text articles as a corresponding or contributing author and has contributed to numerous congress abstracts and posters.


Robert RaffaRobert B. Raffa, PhD
Chief Scientific Officer

Dr. Robert B. Raffa has devoted his professional career to pharmacology and understanding the balance between therapeutic utility and abuse potential of drugs. He was team co-leader for analgesics drug discovery at Johnson & Johnson, where he was involved in the elucidation of the mechanism-of- action of tramadol and the discovery of tramadol combinations. Dr. Raffa has published over 300 peer-reviewed papers, is co-author or editor of several books on pharmacology and is a co-editor of the Journal of Clinical Pharmacy and Therapeutics. He taught at Temple University School of Pharmacy and is adjunct professor at the University of Arizona. He is a past president of the Mid-Atlantic Pharmacology Society, and he lectures and consults worldwide on analgesics and analgesic combinations.


Salma LemtouniSalma Lemtouni, MD, MPH
VP – Regulatory Affairs

Dr. Lemtouni, in her 14 years at the Food and Drug Administration (FDA), acquired deep insight into FDA’s structured approach to Benefit-Risk assessment in drug regulatory decision-making, FDA’s approach to post-marketing safety evaluation and the impetus behind FDA’s policies and regulations.

At FDA’s Division of Cardiovascular and Renal Products, as a Senior reviewer, Dr. Lemtouni guided pharmaceutical industry sponsors into developing sound regulatory plans that furthered drug development programs and achieved approval and marketing of much needed new therapies. At FDA’s Safe Use Initiative, she identified and investigated multiple post-marketing safety signals that led to regulatory action. Dr. Lemtouni was given multiple awards for excellence in review and communication, for her contribution to redesigning New Drug Application review tools and for initiating internal and external collaborations that focused on the safety of FDA approved products.

Previous to her FDA tenure, as a medical officer at Medtronic, Dr. Lemtouni initiated and established the clinical program for the premarket approval of SYNCRATM CRT-P (Cardiac Resynchronization Therapy in heart failure); and as a co-primary investigator, she managed 64 clinical trial centers in one of NIH’s largest studies, ALLHAT (Anti-hypertensive and Lipid Lowering to prevent Heart Attack Trial), the findings of which shaped the guidelines and changed the practice of medicine in the management of hypertension.


Sarah Howlett FaustSarah Howlett Faust
Chief Commercial Officer

Sarah Faust is a senior commercial leader in the pharmaceutical industry with U.S. and global experience. She has a proven track record of launching and growing multi-million to multi-billion dollar brands spanning the specialty, retail and institutional settings.

Sarah’s recent roles include leading all aspects of marketing at Depomed for the relaunch of Nucynta and Nucynta ER from acquisition, through repositioning, strategy development and oversight of tactical execution for launch. Prior to this, Sarah was Vice President of Sales and Marketing, for the specialty dermatology company, PharmaDerm. Here she managed the strategic refocusing of the Company’s portfolio and resource optimization to drive profitability, launched competitive action plans to defend the Company’s leading brand and led growth strategies to double revenues of another. Before PharmaDerm, Sarah held the position of Senior Vice President of Marketing for the specialty pharmaceutical company King Pharmaceuticals, where she oversaw the launch of the first abuse deterrent opioid, prepared launches for a portfolio of others and drove revenues of the Company’s existing pain and hospital based products. Sarah played a pivotal role in the transition of the PharmaDerm and King businesses following their acquisition by Sandoz and Pfizer respectively. Previously, Sarah led the global marketing team for Lovenox, the world’s leading low molecular weight heparin, where she established deep experience in the surgical and institutional settings.

Joseph Pergolizzi Joseph V. Pergolizzi, Jr., MD
Executive Chairman

Joseph V. Pergolizzi, Jr., MD is an internationally recognized thought leader in internal, perioperative and pain medicine, as well as critical and palliative care, pharmacology, drug development and regulatory affairs. An internationally recognized key opinion leader in pain medicine, Dr. Pergolizzi is a top development and regulatory consultant for blockbuster-branded analgesics, such as Nucynta, Cymbalta and Butrans. Dr. Pergolizzi is an experienced C-suite executive who brings an extensive professional network and background in global healthcare to Neumentum.

He is the co-founder of NEMA Research, Inc., a specialty CRO, a former subcommittee member of the FDA SUI and SGE VAH Grant Review for Analgesics, and chairman of PAINWEEK and Consultant to National Pain Foundation Board of Directors. Dr. Pergolizzi is the former director of business development and financial affairs for the Johns Hopkins University School of Medicine Clinical Trials Unit. He also formerly served as a part-time adjunct faculty member in the department of medicine at the Johns Hopkins University School of Medicine.


R. Scott Shively R. Scott Shively
Chief Executive Officer

Scott Shively is an experienced senior leader in the U.S. and international pharmaceutical markets with extensive COO and CCO experience. He has deep expertise in marketing, sales, managed markets and business development/M&As, with demonstrated ability to lead, rapidly create and grow organizations, develop strategy and execute to deliver results and drive rapid growth in sales and value for shareholders.

Scott has most recently served as chief commercial officer and senior vice president for Depomed, where he led the 400-person, six-brand commercial business for the dynamically growing Pain & CNS Specialty Pharmaceutical company. During his time at Depomed, the company’s net sales increased by 199 percent annually, and he led commercial and all functional efforts in a $1.05 billion acquisition and re-launch of the Nucynta products from Johnson & Johnson. Prior to Depomed, Scott served as executive vice president and chief commercial officer of Zogenix, where he directed all commercial efforts of the company, built the commercial organization and launched a new pain product in record time. From 2009 to 2012, he was vice president and global commercial disease area lead for pain for Pfizer, Inc., where he had global commercial leadership responsibility for all of Pfizer’s marketed and development stage pain products, including Lyrica and Celebrex, with accountability for over $6.5 billion in revenues.


August MorettiAugust Moretti
Director

August Moretti joined our Board in April 2019. He is currently the CFO of 4D Molecular Technologies, a privately held gene therapy company.  Augie has extensive operating and financial executive experience in all phases of company growth and funding, from early stage development to product approval and commercialization.   From 2012 to 2018 he was CFO of Assertio Therapeutics, a publicly held specialty pharmaceuticals company focused in pain and neurology, and from 2004 to 2011 CFO of Alexza Pharmaceuticals, a publicly held pharmaceutical company developing drug device combination products for pulmonary delivery of CNS drugs.  From 2001 to 2004 he was CFO and General Counsel of Surromed, a privately held biotechnology company focused on proteomics. Prior to 2001 he was a partner of Heller Ehrman, an international law firm, where his practice included representation of life science companies on issues relating to public and private financings, mergers and acquisitions, corporate governance, disclosure and public reporting.

As CFO of Assertio, Alexza and Surromed he has raised over $1.5 billion in funding, including public and private issuance of equity, convertible debt and secured debt and monetization of royalty interests, has overseen several product acquisitions and has been responsible for 50 consecutive quarters of public company reporting.

Augie holds a B.A. in Economics from Princeton University and a J.D. from Harvard Law School and has taught Finance at UC Berkeley School of Business Administration.


Andrew Scott Blank
Director

A third-generation Miamian, Andy serves on the Executive Committee of the Greater Miami Jewish Federation and on the Board of BioCardia which has developed an individualized stem cell therapy including a unique ability to deliver stem cells directly to the heart muscle for the treatment of congestive heart failure. He has also served as the Chairman of the Florida Public Service Commission Nominating Council, Chairman of the Miami-Dade Community College Foundation (the largest community college in the US), Chairman of the Miami-Dade Community College Presidential Search Committee and was selected by Florida Trend Magazine as an “Up and Comer” Award Winner.

Andy serves as President of: National Brands, Inc., a family office which was, under the leadership of three generations of Blank family, the largest Anheuser-Busch beer distributor in the world; President of WareITis Technologies, LLC, (wareitis.com) which has developed the foremost enterprise level content management software suite; Archive America, (archiveamerica.com) a full-service, off-site records management company. Archive America is the largest family-owned document storage firm in the U.S. with locations in Miami, Tampa, Atlanta, Boston, Worcester, Chicago and Los Angeles; Seaboard Warehouse Terminals (seaboardwarehouse.com), Seaboard Chicago Terminals, and Seaboard Tampa Terminals. Seaboard provides third party logistics, including bonded warehousing, transportation & delivery, and contract storage services to manufacturers and sales organizations that require storage and distribution services for their products throughout the US.

Andy also serves as President of the Blank Family Foundation, (blankfamily.org) a Florida-based private family foundation which provides philanthropic support to a multitude of worthy charitable organizations.

 


Pedro GranadilloPedro Granadillo
Board Member

Pedro is a highly-respected pharmaceutical business leader with over 40 years of experience in the industry and a proven track record in human resources, manufacturing, quality assurance and corporate governance. He boasts expertise in designing and operating complex global manufacturing networks, senior leadership development and succession planning, organizational transformation and portfolio management. He possesses over two decades of international experience, with direct global responsibility for manufacturing, quality and human resources and 13 years in leadership roles in Europe. Pedro served as senior vice president for Eli Lilly until his retirement in 2004 after 34 years of service. Since his retirement from Lilly, Pedro has been involved in a number of public and private companies in the biotechnology and medical device fields. He currently serves on the board of directors of Haemonetics Corporation in Braintree, MA. He previously served on the boards of directors of Dendreon Corporation, Noven Pharmaceuticals, First Indiana Bank and most recently, NPS Pharmaceuticals, which sold to Shire for $5.2 billion in 2015.


Christine MikailChristine Mikail
Board Member

Christine has spent 15 years in the biopharma industry serving in a variety of roles spanning corporate strategy and business development, managing and building operations at start-up companies and constructing and executing on complex financings and life sciences transactions.

Christine served as CAO, head of external business development and general counsel of Axovant Sciences, Inc., which is developing solutions for patients with dementia. Christine was part of the small leadership team of five that took Axovant public in 2015 with a $362 million IPO, the largest biotech IPO in history at the time. Christine built operations from the ground up and led business development at this fast-growing company.

Prior to that, she was senior vice president for legal affairs, general counsel and board secretary at NPS Pharmaceuticals, Inc., where she was an integral part of its sale to Shire Pharmaceuticals for $5.2 billion. Christine also was executive vice president for corporate development at the Dendreon Corporation, where she led the company’s restructurings that culminated in its sale to Valeant. She also held several roles at ImClone Systems and Eli Lilly, including an instrumental role in the sale of ImClone to Lilly for $6.5 billion.

She received her bachelor’s degree from Rutgers University and her JD from Fordham University School of Law.

Paul White, MD, PhD

Distinguished Professor in Anesthesiology and Pharmacology and Former Chairman, Department Anesthesiology. Father of PCA and authority on ketorolac in US.

Eugene Viscusi, MD

Professor in Anesthesiology. Recognized innovator of acute analgesics.

William Schmidt, PhD

Seasoned Analgesic Drug Developer and Global Regulatory Expert.

Charles Argoff, MD

Professor in Neurology. Former NIH. Recognized expert in Chronic Pain.

Bill Loskota, MD, PhD

Distinguished Professor in Anesthesiology and Pharmacology. Pharmacy and Therapeutics expert.

Giustino Varrassi, MD

Professor in Anesthesiology and Former Chairman Anesthesiology. European authority on Ketorolac.

Rami Ben-Joseph, PhD

Health Economics and Outcomes Research.

Frank Breve, PharmD

Professor of Pharmacology and Health Economics and Outcomes Research. Lead consultant for Hospital Formulary Decision Making Teams.